Predictors of lower response to COVID19 vaccine in people living with HIV. A 6-month follow-up study

Le résumé fourni par la source

Abstract Clinical trials demonstrated efficacy and safety of COVID-19 vaccines, although enrolment of immunocompromised individuals, including people living with HIV (PLWH), has been limited. Although cellular immunity is not negligible, recent evidence suggests a strong correlation between neutralising antibody titre and overall protection against infection. Our study aimed to identify potential predictors of lower response to vaccine in PLWH. We conducted a prospective study at the Padua University Teaching Hospital, Italy. Participants were vaccinated with a BNT162b2 2-dose schedule in early 2021. Non-naïve to SARS-CoV-2 were excluded. Anti-S titres were assessed using AdviseDx SARS-CoV-2 IgG II quantitative CMIA assay at 30, 90 and 180 days after completion of vaccination. Non-response was defined as < 50 AU/mL and lower response as the lowest quartile. Information on age, sex, BMI, comorbidities, CD4 count, CD4/CD8, viral load was collected. The association between predictors and lower response was assessed using logistic and linear regression. We enrolled 180 individuals (15 excluded). Mean age 54.0±11.2 years; 17% females; 23% showed CD4 count <500 (none <200), while 18.2% CD4/CD8 <0.5. All responded to vaccine at any follow-up time. Lower response was associated with dyslipidaemias (AOR 4.75; 95%CI: 1.39-16.20; 30 days) and diabetes (AOR 7.11; 95%CI: 1.10-46.10; 90 days), while 1-unit increase in BMI was associated with reduced risk (AOR 0.78; 95%CI 0.64-0.95; 90 days). No correlation was found between anti-S titre and CD4 count (β -0.057; p 0.52), CD4/CD8 (β 0.050; p 0.57) nor viral load (β -0.001; p 0.99). Response to vaccine is good and sustained in well controlled PLWH. Dyslipidaemias and diabetes are associated with a non-concerning lower response. Increased BMI as protective factor may reflect the effect of good nutritional status. Using CD4 count, CD4/CD8 or viral load does not appear to help predict vaccine response in well controlled HIV. Key messages • Well controlled People Living With HIV (PLWH) respond well to BNT162b2 vaccine, and neutralising antibody titres are maintained for up to 6 months after primary vaccination. • PLWH with dyslipidaemias and diabetes have lower antibody persistence, although always above the threshold. Good nutritional status may contribute to longer antibody persistence.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.